|Bid||0.0000 x 1300|
|Ask||0.0000 x 1000|
|Day's Range||0.4810 - 0.4960|
|52 Week Range||0.2500 - 1.3900|
|Beta (5Y Monthly)||1.59|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
You know there was some bad news with a company's quarterly update when the stock tumbles after the results are announced. That's what happened Friday with Bionano Genomics (BNGO). The cytogenetics specialist's shares fell nearly 10% after the announcement of its Q3 results.While Bionano reported $2.2 million in Q3 2020 revenue, slightly ahead of consensus expectations for $2.1 million, it represented a 33% decline year over year. Profits-wise, Bionano reported a $10.8 million net loss (up 69% year over year) as a result of increased research and development spending, and a near-doubling in selling, general, and administrative expenses.Despite the disappointing reaction among investors, two Wall Street investment banks stepped in to reiterate their support of the stock, and to predict that Bionano stock will not only recover its losses, but grow three times in value over the next year... or maybe even four times.Let's begin with the less optimistic of these two notes, from Oppenheimer's Kevin DeGeeter, who rates Bionano Genomics an Outperform (i.e. Buy) and believes that the stock's $0.50-a-share price is going to $1.50 in the next 12 months. (To watch DeGeeter's track record, click here)DeGeeter starts out by noting that $2.2 million was at least "in line" with his own sales estimate of $2.3 million, and that flow cell (glass slides used in DNA analysis) sales were up 34% year over year and up 25% sequentially from Q2 2020. Sales of "consumable" products such as these flow cells are key to DeGeeter's optimism about the stock, which he predicts will make up lost ground in Q4 to close out 2020 with $7.7 million in sales (just a bit below last year's $8 million in sales). DeGeeter expects real growth to appear in 2021, with sales surging to $22.7 million, then nearly doubling again to $40.2 million in 2022.As optimistic as DeGeeter is about the stock, Maxim's Jason McCarthy is even more so, positing a $2 share price on Bionano Genomics 12 months from now, and rating the stock "buy." (To watch McCarthy's track record, click here)Acknowledging the revenue decline year over year, McCarthy blames it on Covid temporarily depressing demand, and also a change in business model to a "rental-reagent model" -- but emphasizes the speed of Bionano's sales rebound, noting that total revenues were up 86% sequentially. Furthermore, McCarthy believes that revenue growth under the new business model will be "more predictable" and less "chunky."McCarthy also believes that Bionano's Saphyr system will prove useful to researchers conducting a large US leukemia study, arguing that "Saphyr offers a simple and high throughput work flow" that is better and cheaper than existing methods of chromosomal analysis. And the analyst cites a "largest-to-date study in undiagnosed genetic disease" being conducted by University of California San Francisco, in which Saphyr again proved than existing "standard of care sequencing and cytogenetic methods" at diagnosing unknown genetic diseases.Perhaps the most curious part of McCarthy's report, however, is that he predicts Bionano's revenues will be much lower than what DeGeeter is calling for both this year ($7.1 million) and next year as well ($19.2 million). Yet even with these smaller revenue numbers, his $2 price target implies 33% more upside in the stock than DeGeeter predicts.Over the past 3 months, only one other analyst has thrown the hat in with a view on the stock. The additional Buy rating provides BNGO with a Strong Buy consensus rating. With an average price target of $1.55, investors stand to take home over 200% gain, should the target be met over the next 12 months. (See BNGO stock analysis on TipRanks)To find good ideas for biotech stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Bionano Genomics (NASDAQ: BNGO) reported Q2 sales of $1.18 million. Earnings fell to a loss of $7.43 million, resulting in a 23.84% decrease from last quarter. In Q1, Bionano Genomics brought in $1.14 million in sales but lost $9.76 million in earnings.What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, Bionano Genomics posted an ROCE of -1.27%.Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.View more earnings on BNGOReturn on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.For Bionano Genomics, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.Q2 Earnings Recap Bionano Genomics reported Q2 earnings per share at $-0.09/share, which did not meet analyst predictions of $-0.09/share.See more from Benzinga * Click here for options trades from Benzinga * 12 Healthcare Stocks Moving In Thursday's Pre-Market Session * Earnings Scheduled For November 12, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
On Thursday, November 12, Bionano Genomics (NASDAQ: BNGO) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.What Are Earnings, Net Income, And Earnings Per Share? Earnings and especially earnings per share (EPS) are useful measures of a company's profitability. Total earnings, which is also referred to as net income, equals total revenue minus total expenses. EPS equals to net income divided by the number of shares outstanding.Earnings And Revenue Analysts are predicting Bionano Genomics will report a loss of $0.05 per share on revenue of $2.07 million. In the same quarter last year, Bionano Genomics reported a loss per share of $0.59 on revenue of $3.31 million.Why Analyst Estimates And Earnings Surprises Are Important Analysts who cover this company will publish forward-looking estimates of its revenue and EPS each quarter. Averaging together every EPS and revenue prediction that each analyst makes about a company in a quarter yields the "consensus estimates." A company posting earnings or revenue above or below the consensus estimate is known as an "earnings surprise" and may move the stock by a considerable margin.View more earnings on BNGOThe analyst consensus estimate would represent a 91.53% increase in the company's EPS figure. Sales would be down 37.52% from the same quarter last year. Bionano Genomics's reported EPS has stacked up against analyst estimates in the past like this:Quarter Q2 2020 Q1 2020 Q4 2020 Q3 2019 EPS Estimate -0.09 -0.21 -0.18 -0.45 EPS Actual -0.09 -0.30 -0.23 -0.59 Revenue Estimate 860.00 K 1.70 M 4.42 M 4.44 M Revenue Actual 1.18 M 1.14 M 2.79 M 3.31 M Stock Performance Over the past 52-week period, shares of Bionano Genomics have declined 49.81%.Do not be surprised to see the stock move on comments made during its conference call. Bionano Genomics is scheduled to hold the call at 16:30:00 ET and can be accessed here.See more from Benzinga * Click here for options trades from Benzinga * Earnings Preview: Globant * Earnings Outlook For Sierra Wireless(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.